Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Clinical trial NCT02699099 · COMPLETED
Trial details
- NCT number
- NCT02699099
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-10
- Primary completion
- 2018-03-14
- Enrollment
- 699
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.